ArticleFrontiers in oncology2021
Case Report: Targeted Therapy for Metastatic Solid Pseudopapillary Neoplasm of the Pancreas With
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Malignant Solid Pseudopapillary Neoplasm of the Pancreas: An Orthogonal Analysis.Annals of surgical oncology · 2024Pooled it
- Solid Pseudopapillary Neoplasms (SPNs) of the Pancreas: Appraisal of Contemporary Clinicopathologic Features - Clinical Implications and Surgical Outcomes of Patients Treated and Followed at a Single Institution.Journal of surgical oncology · 2026Article
- Clinicopathological and molecular features of solid pseudopapillary neoplasms: a retrospective series including a small subset of aggressive cases.Pathology oncology research : POR · 2026Article
- Giant solid pseudopapillary neoplasm of the pancreas in an adolescent girl: a case report with narrative review.Frontiers in oncology · 2026Article
- Ablative stereotactic MR-guided radiotherapy for >10 cm solid pseudopapillary tumor of the pancreas with liver oligometastases: a case report and literature review.Frontiers in oncology · 2026Article
- Sex hormone receptor signaling networks drive pancreatic solid-pseudopapillary neoplasm pathogenesis and therapy.Discover oncology · 2025Review
- Unraveling the enigma: A comprehensive review of solid pseudopapillary tumor of the pancreas.World journal of gastrointestinal oncology · 2024Review
- Solid pseudopapillary neoplasm of the pancreas with hepatic metastases: problems and strategies.Frontiers in oncology · 2024Review
- A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?Therapeutic advances in medical oncology · 2024Review
- Case report: Clinical analysis and literature review of five cases of metastatic solid pseudopapillary tumor of the pancreas.Frontiers in oncology · 2024Article
- The Sex Features of Patients With Solid Pseudopapillary Neoplasms of the Pancreas: A Retrospective Study.Frontiers in oncology · 2022Article
- A refractory liver metastatic solid pseudopapillary neoplasm pancreas harboredFrontiers in oncology · 2022Article
- Endocrine therapy for metastatic solid pseudopapillary neoplasm of the pancreas: A case report.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolid pseudopapillary neoplasm (SPN) of the pancreas shows an indolent clinical behavior in cases undergoing surgical resection. The efficacy of combination therapy in the metastatic extrapancreatic SPN treatment remains largely unknown and a clinical challenge. CASE PRESENTATION: We report a case of a metastatic pancreatic SPN in a 45-year-old woman who presented with an aggressive peritoneal dissemination and hepatic metastases and still showed an indolent clinical course with combination therapy with repeated surgery and targeted therapy. Although the follow-up effect remains to be seen, this is the first report of practical experience of the targeted agents sunitinib and everolimus in metastatic SPN tumors based on the mutation status of
conclusionEvidence on variant genetics indicates that future molecular studies may not only help to explain the mechanism of SPN occurrence and development but are also more likely to direct to future precision treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.